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Abstract 
Sepsis and meningitis due to invasive group B Streptococcus (iGBS) 
disease during early infancy is a leading cause of child mortality. 
Recent systematic estimates of the worldwide burden of GBS 
suggested that there are 319,000 cases of infant iGBS disease each 
year, and an estimated 147,000 stillbirths and young-infant deaths, 
with the highest burden occurring in Sub-Saharan Africa.  The 
following priority data gaps were highlighted: (1) long-term outcome 
data after infant iGBS, including mild disability, to calculate quality-
adjusted life years (QALYs) or disability-adjusted life years (DALYs) and 
(2) economic burden for iGBS survivors and their families. Geographic 
data gaps were also noted with few studies from low- and middle- 
income countries (LMIC), where the GBS burden is estimated to be the 
highest. In this paper we present the protocol for a multi-country 
matched cohort study designed to estimate the risk of long-term 
neurodevelopmental impairment (NDI), socioemotional behaviors, 
and economic outcomes for children who survive invasive GBS disease 
in Argentina, India, Kenya, Mozambique, and South Africa. Children 
will be identified from health demographic surveillance systems, 
hospital records, and among participants of previous epidemiological 
studies. The children will be aged between 18 months to 17 years. A 
tablet-based custom-designed application will be used to capture data 
from direct assessment of the child and interviews with the main 
caregiver. In addition, a parallel sub-study will prospectively measure 
the acute costs of hospitalization due to neonatal sepsis or meningitis, 
irrespective of underlying etiology. In summary, these data are 
necessary to characterize the consequences of iGBS disease and 
enable the advancement of effective strategies for survivors to reach 
their developmental and economic potential. In particular, our study 
will inform the development of a full public health value proposition 
on maternal GBS immunization that is being coordinated by the World 
Health Organization.
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Introduction
The United Nations Sustainable Development Goals (SDGs) 
aim to complete the unfinished agenda for child survival and 
ensure that every child has the opportunity to thrive, including 
reaching their developmental potential1,2. While SDG3 contin-
ues to center on the reduction of neonatal and child mortality, 
SDG4 incorporates specific targets and indicators to address 
early childhood development (UN SDG, 2015). It is recognized 
that preventable infections, such as those that cause meningi-
tis, neonatal sepsis, and pneumonia, are an important cause of 
neonatal and infant death3. However, their contribution to neu-
rodevelopmental impairment (NDI), which encompasses both 
developmental delay (two or more developmental domains in 
children ≤5 years old) and disability (impairment in a child’s 
physical, learning, language, or behavior function) has been 
under-appreciated. As child deaths are reduced in low- and mid-
dle-income countries (LMIC), neurodevelopmental impairment 
may increase, especially if access and quality of early childhood 
developmental programs is sub-optimal4,5.
Invasive group B Streptococcus (iGBS) disease during the first 
months of life is one of the infections that might have impor-
tant long-term consequences for children. This infection often 
presents as sepsis or meningitis and was responsible for an esti-
mated 90,000 (uncertainty range [UR]: 36,000-169,000) infant 
deaths in 20156. Survivors of iGBS disease in early life may 
develop long-term NDI. Of 18 studies identified in a recent review 
of the risk of NDI in children with history of iGBS disease7, 
only three were from middle-income countries and none were 
from low-income countries where the majority of iGBS dis-
ease cases occur. In these studies, NDI was defined as problems 
of body function and structure, such as significant deviations or 
loss in intellectual and/or motor, vision, or hearing impairment. 
The review concentrated on infants with GBS meningitis, high-
lighting a key data gap related to long-term adverse outcomes 
in infants who develop GBS-associated sepsis. Furthermore, 
only a small number of older studies (primarily from the 1970s) 
reported NDI outcomes in children older than 2 years, which 
would have missed impairment outcomes that do not manifest 
until later in childhood.
Intrapartum antibiotic prophylaxis (IAP) has reduced the inci-
dence of early-onset iGBS disease in some high-income coun-
tries8,9; however, this approach is less effective in preventing 
late-onset invasive disease10 and thought not to significantly 
affect other consequences of maternal GBS colonization, notably 
GBS-associated stillbirths and preterm births. Maternal vacci-
nation against GBS is a promising alternative that could protect 
both mothers and infants against iGBS disease. To guide invest-
ment in maternal vaccines targeting GBS, it is necessary to esti-
mate the health and economic burden caused by the disease 
globally11. Studies on mortality and morbidity due to GBS among 
pregnant and postpartum women, stillbirths, and infants have 
been recently reviewed and meta-analyzed12. These reviews uncov-
ered two major data gaps that significantly hinder these analyses: 
the lack of long-term follow-up data amongst survivors, which 
are needed to calculate generic health-related utility measures 
such as quality-adjusted life years (QALYs) or disability-adjusted 
life years (DALYs) to allow comparison with other diseases, 
and the lack of primary data regarding long-term economic con-
sequences to households of children with a history of iGBS 
disease.
Data on the costs associated with iGBS disease, which are 
needed to inform cost-effectiveness analysis and investment 
decisions on the development and deployment of new vaccines, 
are scarce. We are only aware of a single study undertaken in 
the UK that directly assessed the economic costs of iGBS dis-
ease beyond the acute episode13. This showed that over the first 
two years of life, the health and social care costs of infants with 
a history of iGBS disease were almost twice that of children with 
no history of iGBS disease. Although there are more studies that 
report on the acute costs of infant sepsis/meningitis, these are 
generally from high-income countries and are not GBS etiol-
ogy specific14. To better understand the life-course consequences 
of infant iGBS, data on health and economic outcomes needs to 
be collected in studies that include older children and adolescents 
across multiple settings.
In this paper, we present the protocol for a multi-country epide-
miological study. The main aim of the study is to estimate the 
risk of NDI and socioemotional behaviors in children who sur-
vived neonatal or infant iGBS. The study will also measure 
long-term health related quality of life (HRQoL) and economic 
costs that arise as a consequence of iGBS, as well as the acute 
costs of sepsis and meningitis in young infants. This study, 
coordinated by the London School of Hygiene & Tropi-
cal Medicine, is part of a collaboration with the World Health 
Organization (WHO) to inform the development of a value 
proposition for maternal vaccines against GBS.
Research objectives
Our objectives in designing this study were:
Objective 1 - Long-term neurodevelopmental impairment:
(a)    Primary objectives:
1.    To estimate the risk of moderate/severe NDI in chil-
dren with history of iGBS disease in early-infancy, 
and to compare this with the risk in children with 
no known history of iGBS
2.    To estimate the risk of mild and moderate/severe 
socioemotional behavior outcomes in children 
with history of iGBS, and compare with risk in 
children with no known history of iGBS
(b) Additional objectives:
1.    To estimate the risk of mild impairment
2.    To estimate the risk of multi-domain and domain- 
specific neurodevelopmental impairment
3.    To estimate the risk of adverse growth outcomes 
(e.g., stunting, wasting)
4.    To estimate the risk of epilepsy
Objective 2 – Long-term mortality: To assess mortality beyond 
initial hospital-discharge among children who had iGBS.
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Objective 3 – Long-term economic costs and health-related 
quality of life:
(a)    Long-term economic consequences: To measure the 
long-term economic costs to the healthcare system, 
households and society associated with infant iGBS.
(b)    Health-related quality of life: To collect information 
needed to calculate the difference in QALYs between 
children with a history of iGBS, and those with 
no history of iGBS.
Objective 4 – Short-term economic consequences: To esti-
mate the costs to the healthcare system and households during 
acute episodes of sepsis and meningitis (irrespective of etiology) 
in neonates and young infants.
Protocol
Study design
Long-term outcomes after iGBS disease in infancy (Objectives 
1, 2, 3). We will use a matched cohort study design to collect 
data on NDI, socioemotional behavioral, and economic out-
comes for survivors of iGBS in early infancy. Children with 
a history of infant iGBS (henceforth iGBS survivors), will 
be identified via hospital records in study sites, Health and 
Demographic Surveillance Systems (HDSS), or among partici-
pants of previous epidemiological studies. Children with no his-
tory of iGBS (henceforth, the non-iGBS comparison group) 
will be identified and matched to iGBS survivors based on 
sex and birth month and year. 
Acute costs of neonatal sepsis and meningitis study (Objec-
tive 4). In addition to the main study measuring long-term 
economic outcomes, we will undertake a separate study to 
quantify the acute costs to the healthcare system and household 
linked to neonatal sepsis and meningitis. This study will involve 
a different study population: prospectively identified neonates 
admitted for clinically suspected sepsis or meningitis irrespec-
tive of the underlying etiology. Data on the costs associated with 
the period of acute hospitalization will be collected following 
discharge.
Study settings and teams
Since the major data gap on the long-term outcomes of iGBS 
survivors is in LMICs, this study was designed to collect data 
in these settings, including at least one country per GBS high-
burden region (Africa, Asia, Latin America). For this col-
laborative work, we shared a call for data through multiple 
channels in 2018, including targeting previous collaborators, 
experts and known GBS researchers, scientific conferences and 
meetings, as well as sending direct requests from WHO head-
quarters to country offices and placing posts on social media 
platforms to reach the widest number of people. With these vari-
ous approaches we aimed to ensure better geographical repre-
sentation than currently seen in the literature. Among those who 
responded, potential study sites were identified based on the 
following criteria: (a) sites that had at least 10 post-discharge 
surviving iGBS cases that could be enrolled; (b) sites that had 
neurodevelopmental follow-up data or the ability to collect this 
type of data in children aged at least 3 years; (c) sites where the 
expected loss to follow-up was <20%. From those who expressed 
an interest in joining this project and fulfilled the above cri-
teria, research teams from Argentina, India, Kenya, Mozam-
bique and South Africa agreed participate in this work and lead 
investigations locally (Table 1).
In Argentina, the local study will be performed by the research 
organization Fundación Infant, in Buenos Aires; in Southeast 
India, the research activities are led by the Christian Medical 
College in Vellore; in Kilifi, Kenya, the work is being under-
taken by KEMRI-Wellcome Trust Research Programme; in 
Mozambique, children are being recruited at the Manhiça Health 
Research Centre, in collaboration with the Barcelona Institute 
for Global Health; and in South Africa, the project is being led 
by the South African Medical Research Council Vaccines and 
Infectious Diseases Analytical Research Unit (VIDA).
Long-term health outcomes after GBS invasive disease 
in infancy (Objectives 1, 2 & 3)
Study populations. In the Kenya and Mozambique sites, which 
are also HDSS sites, parents of potential study participants, 
based on the HDSS database, will be contacted through stand-
ard recruitment procedures. Hospital records, which are linked 
to the HDSS database, will be used to identify all children who 
have been admitted with iGBS based on the case defini-
tion. The HDSS database will also be used to select matched 
non-iGBS children from the community. 
In Argentina and India, hospital-based databases will be 
used to identify potential iGBS survivors and non-iGBS 
children using standard practices established by each site. 
Hospital-based databases will be used to identify children who 
have been admitted with iGBS based on the case definition. 
Hospital-based birth registries will be used to select matched 
non-iGBS children. 
In South Africa, the same cohort of iGBS survivors and con-
trols from three epidemiological studies that were conducted 
between 2012 and 2015 will be contacted for re-enrolment. 
These participants are expected to be 5–7 years old and origi-
nally consented to be followed until the age of 5. Using the 
study database, parents or primary caregivers of these children 
will be contacted by phone for interest and be given information 
about participating in the new study.
Invasive GBS disease case definition. Children with a previ-
ous diagnosis of either GBS meningitis or GBS sepsis in the 
first 90 days of life (days 0 - 89) will be recruited in these local 
epidemiological studies. Enrolment of children with a history 
of GBS sepsis is important to increase the, currently limited, 
number of studies with data on long-term disability post-GBS 
sepsis7. Table 2 below summarizes the case definition and the 
clinical and microbiological eligibility criteria used by each 
study site for identification of exposed children in this study.
Sample size and power calculation. The number of iGBS sur-
vivors included in the matched cohort study of long-term 
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Table 1. Description of collaborative research partners and study population participating in long-term and acute cost 
studies.
Country 
of data 
collection
Collaborative 
Institute(s) Facility type
Long-term outcomes study (Objectives 
1,2,3) Acute cost study (Objective 4)
Identification 
of GBS-
exposed 
children
Identification 
of GBS-
unexposed 
children
Age at 
enrolment
Identification of 
meningitis/sepsis
Age at 
enrolment
Argentina
Fundación 
Infant, 
Buenos Aires, 
Argentina
2 Public 
hospitals in 
Tucuman area
Neonates 
admitted with 
GBS sepsis 
or meningitis 
from 2003–
2016
Primary Care 
Centers that 
belong to 
the Maternity 
Network
3–16 years
N/A N/A
India
Christian 
Medical 
College (CMC) 
Vellore, Tamil 
Nadu, India
Academic 
and referral 
hospital at 
CMC Vellore
Hospital-
delivered 
neonates 
admitted from 
2004–2018
Hospital birth 
registry
18 months 
– 15 years
Sepsis with positive 
blood culture. 
 
Meningitis with either 
positive CSF culture 
or suggestive CSF 
counts or protein 
0–89 days 
old
Kenya
KEMRI-
Wellcome 
Trust, Kilifi, 
Kenya
Kilifi County 
Hospital / 
KEMRI
Admitted with 
GBS from 
2007–2018
Health 
Demographic 
Surveillance 
System
1–12 years
Sepsis with positive: 
blood culture 
 
Meningitis with 
positive CSF culture 
or suggestive CSF 
counts or protein
Mozambique
Barcelona 
Institute for 
Global Health, 
Barcelona, 
Spain Manhiça 
District 
Hospital
Isolated 
during routine 
morbidity and 
microbiological 
surveillance 
conducted 
2001–2018
Health 
Demographic 
Surveillance 
System
3–17 years
Sepsis with positive 
blood culture or 
clinically presumed 
sepsis 
 
Meningitis with 
positive CSF culture 
or suggestive CSF 
counts or protein; or 
clinically presumed 
meningitis
Manhiça 
Health 
Research 
Centre, 
Manhiça, 
Mozambique
South Africa
Wits Health 
Consortium, 
Johannesburg, 
South Africa
3 Academic 
hospital in 
Johannesburg
Surveillance of 
the pediatric 
wards and 
microbiology 
services at the 
three hospitals 
from 2012–
2015
Unexposed 
children 
enrolled 
during 
a similar 
time-period 
as exposed 
children
5–7 years
Sepsis with positive 
blood culture 
 
Meningitis with 
positive CSF culture, 
latex agglutination, 
PCR or suggestive 
CSF counts
Table 2. Case definition of invasive GBS disease used for recruitment (adapted from 15).
Clinical syndrome Case definition used in this study
Possible serious 
bacterial infection 
(pSBI)
Any one of the following: a history of difficulty feeding, history of convulsions, movement only when 
stimulated, respiratory rate of 60 breaths per min or more, severe chest in-drawing, temperature ≥ 
37.5°C or ≤35.5°C
Sepsis Clinical signs of pSBI and/or GBS-positive blood culture or PCR or latex agglutination
Meningitis Clinical signs of pSBI and [(GBS-positive CSF culture or PCR or latex agglutination) or (GBS-positive 
blood culture or PCR or latex agglutination and CSF leucocyte count of >20x106/l)]
pSBI, possible serious bacterial infection; CSF, cerebrospinal fluid; PCR, polymerase chain reaction.
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outcomes was based on the maximum number of cases expected 
to be identified, accounting for 20% being unreachable, ineligible 
or who refuse participation. The expected number of iGBS survi-
vors for each site is summarized in Table 3. Based on anticipated 
recruitment of 200 iGBS survivors and a 1:3 ratio of matched 
non-iGBS children, and assuming a prevalence of our primary 
outcome (moderate/severe NDI) of 26% in iGBS survivors and 
10% in the non-iGBS comparison group (based on a study of 
meningococcal serogroup B survivors16), a pooled analysis would 
be able to detect this difference using a two-sided test of bino-
mial proportions with 99% power at a 5% significance level. 
Mild developmental impairment is likely to be more prevalent 
among iGBS survivors, including those with sepsis. Our power 
to detect a difference in the risk of overall NDI (including mild 
NDI) would be 78%, assuming detection of 32% and 20% 
NDI in iGBS survivors7 and non-iGBS children17, respectively.
Study procedures and data collection. Trained fieldworkers 
will contact the parents/primary caregivers of these potential 
participants about the study by phone (Argentina, India, South 
Africa) or in-person (India if phone contact information is not 
available, Kenya, Mozambique) and those contacted will be 
asked to make a one-time visit to the health facility with their 
child. Reasons for non-participation, such as migration, refusal 
or death will be recorded.
Children enrolled in the study and their main caregiver will 
receive an in-person assessment visit. Written informed con-
sent will be obtained in-person either at the time of the ini-
tial house visit or before the in-person assessment visit. Only 
if appropriate consent/assent is obtained, will the child be enrolled 
in the study. 
At the in-person assessment visits, the following information 
will be collected:
-    Questionnaire to collect participant details including birth 
and medical history, education, household demographic 
and socioeconomic data, as well as economic outcomes 
(for details on economic outcomes see section Economic 
outcomes and health related quality of life)
-    Age-specific neurodevelopmental assessment tools includ-
ing several domains (motor, vision, hearing, cognitive, 
language, socioemotional), an epilepsy screening ques-
tionnaire, and anthropometric measures (see section on 
Assessment of developmental outcomes)
 -    EQ-5D-3L questionnaires to assess the health-related 
quality-of-life (HRQoL) of study participants and their 
main caregiver (see section Economic outcomes and 
health related quality of life).
Data will be collected on paper forms or using a customized 
app (developed in collaboration with icddr,b, Bangladesh). The 
customized Android tablet-based app includes questionnaires 
and neurodevelopment assessment tools, translated into local 
language where relevant (Figure 1).
Assessment of neurodevelopmental impairment (Objective 1). 
In this multi-country study, we will use several tools to diagnose 
Table 3. Expected number of children with 
history of iGBS, by site, for the long-term 
outcomes study.
Site/Country Expected number children 
with history of iGBS
Argentina 40
India 30
Kenya 50
Mozambique 40
South Africa 40 
Figure 1. Screenshots from the customized data capture app.
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NDI and socioemotional and behavioral outcomes in children 
over a wide age range from 18 months to 17 years old. 
The inclusion of children older than those enrolled in the major-
ity of the previous epidemiological studies enables us to use 
more complex developmental assessments designed for older 
ages to detect specific mild NDI and other developmental delays. 
By including a wider age range, we can also better under-
stand the developmental trajectory of infants who have survived 
iGBS. The developmental domains of interest are motor, vision, 
hearing, cognitive, language, and socioemotional; their defini-
tions, by severity, are described in the Data analysis section. 
We will also explore growth outcomes and epilepsy.
The diagnostic tools used to identify NDI and other develop-
mental measurements will be administered by experienced 
assessors, clinical psychologists and pediatricians, who will also 
perform clinical exams to identify impairment in hearing, motor 
and vision domains. Each local research team decided which 
neurodevelopmental assessment tools are appropriate for their 
setting, based on child’s age and cultural appropriateness or 
validation of the instrument and technical capacity of each site. 
There will be 26 different assessment tools and tests being used 
across the 6 neurodevelopmental domains, as well as anthro-
pometric measurements for growth and an epilepsy screen-
ing questionnaire. Table 4 shows the matrix of assessments for 
Table 4. Neurodevelopment assessment tools and other developmental assessment 
measures, by site and age.
Sites
Argentina India Kenya Mozambique South 
Africa
Motor
< 5 years old Pediatric 
clinical exam
BSID* 
 
BOT‡
KDI* MDAT N/A
5 – < 10 years old BOT‡ Bolts and Nuts 
 
Bead Threading
CANTAB GMDS-
ER
≥ 10 years old Stork Balance 
 
Ball Balance
N/A
Cognition
< 5 years old WPPSI† BSID* 
 
WPPSI†
KDI* 
 
Big/small stroop
MDAT N/A
5 – < 10 years old WPPSI† 
 
WISC 4¥
WPPSI† 
 
WISC 5¥
RCPM 
 
Tower of London
CANTAB GMDS-
ER
≥ 10 years old WISC 4¥ WISC 5¥ RCPM 
 
Trail Making
N/A
Language
< 5 years old WPPSI† BSID* KDI* 
PVT, 
Measures of pragmatics
MDAT N/A
5 – < 10 years old WPPSI† WPPSI† Kilifi Naming Test 
 
Measure of Pragmatics 
and Syntax
CANTAB GMDS-
ER
≥ 10 years old WISC 4¥ WISC 5¥ N/A
Hearing
≤ 4 years old Screening test: Distraction test 
Further testing: ABR
N/A
> 4 years old Screening test: Tuning fork, Diagnostic memory audiometer 
Further testing: ABR
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each developmental domain, by age category and study site. 
When a need for further assessment and clinical management 
is identified, children will be appropriately referred into each 
site’s existing referral systems. 
Mortality outcome (Objective 2). Whenever feasible, data on 
the cause of death will be captured through a variety of meth-
ods, including by reviewing medical records, verbal autopsy 
reports and interviews with parents, for iGBS survivors who 
died after the acute episode and before enrolment and for 
matched non-iGBS group who died. In Kenya, the list of 
iGBS survivors who could potentially be enrolled in the study 
only included children alive at the time of enrolment, therefore 
data on early mortality post-iGBS disease will not be collected in 
these sites.
Long-term economic costs and health-related quality of life 
outcomes (Objective 3). There are only limited data avail-
able on the economic consequences of iGBS, which cover only 
healthcare costs in the first two years of life14. In this study, we 
will collect information on variables that will allow compari-
sons of economic outcomes in families of iGBS survivors versus 
families of the non-iGBS comparison group. These data will also 
be used to inform future economic analyses that will be performed 
to assess the value of maternal vaccines against iGBS.
A summary of key economic variables is shown in Table 5. 
Information collected will include details of the monthly 
household income and expenditure, participating children’s 
healthcare utilization, out-of-pocket payments, and any expendi-
ture on social care or special education in the 12 months preced-
ing study enrolment. Additionally, information will be collected 
on time spent by the main caregiver providing informal care 
to the participant, as well as information on the costs of coping 
strategies, such as borrowing and asset sales. Information on the 
HRQoL of both the participant and the main caregiver will 
be collected using an EQ-5D-3L questionnaire in three coun-
tries where country-approved translations are available: Argen-
tina (Spanish), India (English, Telugu, Tamil) and South Africa 
(English, Zulu).
Acute costs of neonatal sepsis and meningitis 
(Objective 4)
Case definition for neonatal sepsis and meningitis. To be able 
to collect data on acute costs, both cases of severe neonatal infec-
tion linked to GBS and cases of severe neonatal infection due 
to other bacteria will be enrolled, as the number of confirmed 
iGBS cases per hospital is anticipated to be small over the dura-
tion of our study. Participants will be babies admitted with a 
diagnosis of clinically suspected neonatal infection (sepsis or men-
ingitis) combined with isolation of a pathogenic microbiological 
agent by culture or detection by polymerase chain reaction 
(PCR) in a normally sterile site (blood/CSF) on day 0 – 89 of 
an infant’s life. Babies born at <32 weeks of gestational age, 
born with severe congenital abnormalities, or with culture posi-
tive results only for organisms considered to be contaminants 
Sites
Argentina India Kenya Mozambique South 
Africa
Vision
≤ 3 years old LEA symbols Chart or Picture chart N/A
> 3 years old Visual acuity app/Tumbling E chart/Snellen chart
Socioemotional
≤ 6 years old CBCL-preschool
> 6 years old CBCL- school aged
Epilepsy
All ages Epilepsy Screening Questionnaire (ESQ)
*BSID assessment up to 42 months.
† WPPSI assessment in Argentina 3-7 years. WPPSI assessment in India 4-7 years.
‡ BOT assessment ≥4 years.
¥ WISC 4 and WISC 5 assessment ≥7 years.
ABR, auditory brainstem response; BOT, Bruininks-Oseretsky Test; BSID, Bayley Scales of Infant and Toddler 
Development;
CANTAB, Cambridge Neuropsychological Test Automated Battery; CBCL, Child Behavior Checklist; GMDS-ER, Griffiths 
Mental
Development Scales – Extended Revised; KDI, Kilifi Developmental Inventory; MDAT, Malawi Developmental 
Assessment Tool; PVT, Picture Vocabulary test; RCPM, Raven’s colored progressive matrices; WISC, Wechsler 
Abbreviated Scale of Intelligence; WPSSI, Wechsler Preschool and Primary Scales of Intelligence.
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or skin commensals will be excluded (Table 6). In Mozambique 
the cases will be defined based on clinically suspected sepsis 
or meningitis because the number of bacteriologically con-
firmed cases is anticipated to be low due to the size of the 
hospital.
Sample size. At least 20 participants will be recruited in each of 
the four sites. The sample size of 20 per site was set as a prac-
tical minimum, considering both available resources and 
also a consensus by local research teams that this would be a 
feasible number to capture given the anticipated number of 
neonatal infections within the timeframe of data collection 
activities. 
Study procedures. Participants will be identified prospectively 
either on admission or using clinical databases. Additionally, 
in India recent cases (within three months before the start of 
the study) will also be identified retrospectively from clinical 
records. Details on hospital resource use will be collected from 
medical records, including information on length-of-stay, type 
of hospital bed, and details of any drugs, diagnostic tests and 
surgical procedures. To capture the wider impacts of a partici-
pant’s hospitalization, a questionnaire will be administered to the 
main caregiver, either at time of discharge, or by follow-up as 
soon as possible after discharge, to collect details on household 
demographics and economic impact. This will include any 
out-of-pocket payments, costs related to travel, accommodation, 
Table 5. Economic data to be collected as part of the long-term and acute cost studies.
Category Measures Acute Long-term
Participant characteristics Participant details including date of birth, gender and ethnic group. 
Relevant medical history including HIV status, gestational age at birth, and 
birthweight. 
Educational status.
Yes Yes
Caregiver characteristics Age, gender, and relationship to the child. 
Education level and occupation.
Yes Yes
Household characteristics Number, relationship to patient and ages of other household occupants. 
Education level and occupation of head of household and mother. 
Household income and welfare received. 
House-hold socioeconomic status based on local asset index. 
Household location (urban / rural).
Yes Yes
Healthcare resource use 
during acute episode
Length-of-stay by bed type (e.g. ICU vs general bed) and days of supportive care 
(e.g. ventilation, NG tube, Oxygen, IV fluids). 
Diagnostics (e.g. lumbar puncture, blood tests, blood/CSF cultures, diagnostic 
imaging) and medicine use.
Yes No
Household expenditure Total household expenditure including separate expenditure on health, transport, 
education, and food.
Yes Yes
Participant HRQoL For long-term cohorts a self-reported EQ-5D-3L for children aged 11 and over; a 
proxy-reported EQ-5D-3L for children aged 3 to 11. 
For the acute cost study, a proxy-reported Visual Analogue Scale. 
Yes Yes
Caregiver HRQoL A self-reported EQ-5D-3L. Yes Yes
Participant healthcare & 
out-of-pocket payments
Number of visits and number of days admitted to a hospital. 
Number of visits to healthcare facilities or traditional healers, and home visits by 
community healthcare professionals. 
Out-of-pocket payments on healthcare including drug costs, travel and 
accommodation and caregiver time spent accompanying participants to hospital.
Yes Yes
Participant social care & out-
of-pocket payments
Use of and cost of special educational services. 
Use of and cost of professional care in the home. 
Provision and cost of any home modifications.
No Yes
Informal caregiving Time spent by the main caregiver providing care to the participant. 
Amount of paid work, subsistence work, housework foregone due to caregiving.
No Yes
Cost of coping Borrowing to cover healthcare and social care costs, or as the result of being 
unable to work. 
Value of assets sold to cover costs. 
Other coping mechanisms.
Yes Yes
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and caregiver time. Data will be gathered on the main caregiver’s 
HRQoL using an EQ-5D-3L questionnaire and the main 
caregiver will be asked to estimate their child’s HRQoL during 
their time in hospital using a Visual Analog Scale (VAS). The 
main caregiver will be encouraged to accompany the child to the 
assessment visit, but in the cases where they do not then these 
sections of the questionnaire will not be completed. No ques-
tionnaires will be administered in the case that a participating 
child dies in hospital, but data will still be collected from 
hospital records.
Data management
Data will be stored on secure servers locally after the end 
of the study, and anonymized data will be transferred to the 
team at the London School of Hygiene & Tropical Medicine, 
where data from different countries will be pooled. Analyses 
will be conducted jointly by all study partners.
Analysis plan
Objective 1 - Long-term neurodevelopmental impairment. To 
allow comparison between the different neurodevelopmental 
assessments being used in each of the five sites, we will under-
take a mapping activity across all 26 tools by age bands (1–4, 
5–9, 10+). The age bands are constructed based on key periods of 
development15. We will map similar constructs across the differ-
ent assessments; e.g., gross motor measurements from all rel-
evant tools will be mapped against each other allowing us to 
compare gross motor development across sites. We will do this 
for the following domains; gross motor, fine motor, cognitive 
and language. We will also do a similar mapping activity 
between the preschool and school-aged CBCL for the socioemo-
tional and behavioral outcomes (e.g., anxiety, ADHD, and autism). 
Definitions domain-specific neurodevelopmental impairment 
and severity are described in Table 7.
In India, Kenya, Mozambique, and South Africa, motor and 
cognitive scores will be normalized using standard refer-
ence populations by assessment and site. In Argentina, where 
motor impairment is being assessed through a clinical exam, 
description of functional impact will be used.
Vision impairment will be defined using WHO categories of 
mild (visual acuity in best eye ≤6/12), moderate (visual acu-
ity in best eye ≤6/18 and >6/60), severe (visual acuity in best 
eye ≤6/60 and >3/60), and blindness (visual acuity in best eye 
≤3/60)18,19.
Any hearing impairment will be defined as an unaided hear-
ing threshold in the best ear of >26 decibels and further cat-
egorized into mild (audiometric hearing threshold level 26–30 
decibels), moderate (threshold level 31–60 decibel), and severe/
deafness (threshold level >60 decibel)18,20. In South Africa 
and Mozambique, screening tests will be used first to iden-
tify any individual with any potential hearing impairment. 
Results from further diagnostic tests will be used to classify into 
impairment severity as categorized above.
Socioemotional behavior measures will be defined in all sites 
using the CBCL assessment. The main scoring is based on a 
principal components analysis that grouped sets of behaviors 
into different syndrome scales: (1) internalizing problem scales, 
which include anxious/depressed, withdrawn-depressed, and 
somatic complaints scores; and (2) externalizing problem scales, 
which includes rule-breaking and aggressive behavior. There 
is also a total problem score which is the sum of all the items. 
Each syndrome, internalizing and externalizing problem score, 
and total score can be categorized into normal (<93rd percen-
tile), borderline (93rd-97th percentile), or clinical behavior 
(>97th percentile) based on the same normative samples to create 
standard scores based on sex and age for all sites.
Primary outcomes
There are 2 primary outcomes in this study, moderate/severe 
NDI and moderate/severe behavioral outcomes.
Moderate/severe NDI will be defined as:
-    Score of >2 SD below the standardized reference mean 
in cognition AND/OR motor composite measures
-    AND/OR hearing loss
-    AND/OR vision loss
Moderate/severe behavioral outcomes will be defined by scores 
within clinical ranges of ≥1 domain(s) of the problem scales.
Additional outcomes
Mild NDI (including socioemotional behavior outcomes) will 
be defined as:
Table 6. Selected organisms considered possible 
contaminants or skin commensals for neonatal 
infection (non-exhaustive list).
Excluded organism
Coagulase-negative Staphylococcus
Bacillus spp.
Micrococcus spp.
Corynebacterium spp.
Propionibacterium spp.
Diphtheroids
Aerococci
Brevundimonas vesicularis
Ochrobactrum anthropi
Staphylococcus saprophyticus
Burckholderia/ NFGNB (if in first three days of life)
Enterococcus (if baby asymptomatic)
Cultures which show poly-microbial growth 
(unless baby has had abdominal surgery / or if it 
includes GBS/E coli)
Any bacterium which shows growth after 72 hours 
of life
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-    Score of 1-2 SD below the standardized reference mean 
in cognition AND/OR motor composite measures
-    AND/OR mild hearing loss
-    AND/OR mild vision loss
-    AND/OR borderline clinical range in at least one domain 
of the problem scales from the CBCL
We will further assign individuals into the following multi- 
domain impairment categories based on severity (adapted from21):
-    Mild if child is classified as mildly impaired in ≤2 domains
-    Moderate if child is classified as mildly impaired in 
3 domains OR classified as moderately impaired in 1 
domain & classified as mildly impaired in 2 domains
-    Severe if child is classified as moderately impaired in 
≥2 moderate domains OR severely impaired in ≥2 domains
The distribution of mild and moderate/severe neurodevelop-
mental outcomes will be summarized for children with his-
tory of iGBS disease and the non-iGBS comparison group and 
Table 7. Definitions of growth and domain specific neurodevelopmental impairment severity.
Domain and severity Severity definition used in this study
Motor Mild Motor for age Z-score -1 to -2 SD for test OR outside normal range of standardized motor score 
for mild classification OR no functional motor impairment from physical exam
Moderate Motor for age Z-score -2 to -3 SD for test OR outside normal range of standardized motor score 
for moderate classification OR moderate functional motor impairment from physical exam
Severe Motor for age Z-score ≤3 SD for test OR outside normal range of standardized motor score for 
severe classification OR moderate functional motor impairment from physical exam such as 
cerebral palsy
Intellectual Mild Cognitive for age Z-score -1 to -2 SD for test (DQ 70-84)
Moderate Cognitive for age Z-score -2 to -3 SD for test (DQ 55-69)
Severe Cognitive for age Z- score ≤3 for test (DQ <55)
Language Mild Language for age Z-score -1 to -2 SD for test OR outside normal range of standardized language 
score for mild classification 
Moderate Language for age Z-score -2 to -3 SD for test OR outside normal range of standardized language 
score for moderate classification 
Severe Language for age Z-score ≤3 SD for test OR outside normal range of standardized language score 
for severe classification 
Vision Mild Visual acuity in best eye <6/12 but better or corresponding visual field loss
Moderate Visual acuity in best eye between 6/18 and 6/60, or corresponding visual field loss
Severe Visual acuity in best eye between 6/60 and 3/60, or corresponding visual field loss
Blindness Visual acuity in best eye <3/60, or corresponding visual field loss
Hearing Mild Audiometric hearing threshold level 26-30 decibel
Moderate Audiometric hearing threshold level 31-64.9 decibel
Severe or 
deafness
Audiometric hearing threshold level ≥65 decibel
Socioemotional/ 
behavioral
Mild CBCL scores within borderline clinical range in at least one domain of the problem scales
Moderate or 
severe
CBCL scores within clinical range ≥1 domain(s) of the problem scales
Epilepsy Had at least one seizure in the last month
Growth Stunted Height for age Z-score < -2
Underweight Weight for age Z-score < -2
Head 
circumference
Head circumference for age Z-score < -2
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further stratified by clinical syndrome (sepsis and meningitis). 
We will test the association between history of iGBS disease in 
early-infancy and moderate/severe NDI in a pooled analy-
sis using a logistic regression accounting for matching factors 
of age and sex. As gestational age is likely to be an important 
confounder, we will adjust for this, if the data allows.
Objective 2 - Mortality. For iGBS survivors, and their matched 
non-iGBS comparison group, that were reachable (i.e. for whom 
we have information), we will describe the proportion of chil-
dren who died before enrolment in each site. Where availa-
ble, we will also describe the causes of death in both iGBS and 
non-iGBS groups.
Objective 3 - Long-term economic and health-related qual-
ity of life. We will assess the impact of iGBS on economic 
outcomes including healthcare utilization and costs, household 
out-of-pocket payments, household income and social care pay-
ments, and time spent by the main caregiver on informal care. 
The cost of hospital stays and attending outpatient clinics will 
be estimated using published unit costs (e.g. WHO-CHOICE)22. 
We will compare these outcomes between the iGBS and non-
iGBS groups in each study site. If data allow, we will also ana-
lyze differences in costs and healthcare utilization linked to 
NDI. Information from EQ-5D-3L questionnaires will be used 
to estimate differences in QALYs of both children and their 
caregivers associated with a history of iGBS disease.
Objective 4 – Acute costs of neonatal sepsis and meningitis. 
Data from the sub-study on acute costs will be used to esti-
mate the average length-of-stay, use of supportive care, drugs 
and diagnostics, during hospitalization for the acute neonatal 
sepsis/meningitis episode. These data will also be used to 
calculate the overall cost per episode. Other variables will be 
presented descriptively to characterize the impact of severe 
neonatal infection.
Ethics
Written informed consent will be obtained from parents or guard-
ians. Whenever appropriate, based on local guidelines, assent 
will also be obtained from children participating in the study. 
The overarching protocol for this multi-country observational 
study was granted ethical approval at the London School of 
Hygiene & Tropical Medicine (approval number 16246). Insti-
tutional review boards in each of the operating countries granted 
ethics approval (Argentina approval number Protocol EGB-1, 
India approval numbers 11723 (CMC Vellore), 2019–7034 
(ICMR); Kenya approval number SERU/CGMR-C/164/3882; 
Mozambique approval numbers 98/CNBS/2019; South Africa 
approval number M190241), as well as the institutional review 
board of the World Health Organization (approval number 
ERC.0003169).
Discussion
This multi-country study will provide new data on the conse-
quences of iGBS, which is responsible for significant morbid-
ity, disability and mortality in infants9,17. In particular, we will 
provide novel data on NDI and socioemotional and behavior 
outcomes, especially in LMIC contexts. Previous reviews have 
not included any low-income country data, outcomes due to 
GBS-associated sepsis, or mild NDI15. Mild NDI may be com-
mon, impact families and societies, and are required to estimate 
DALYs, which are widely used as metrics to set priorities for 
resource allocation.
An important strength of this study is the inclusion of older 
children (3–17 years) representing three continents (Latin Amer-
ica, Africa, Asia), which currently have limited local data on NDI, 
socioemotional behavior outcomes, and wider socioeconomic 
consequences following iGBS disease. This will allow better 
understanding of the geographic variability on the risk of long-
term disability linked to GBS. No previous studies have reported 
on the potential long-term (>2 years) consequences of GBS 
in these countries7. Furthermore, our study population will include 
both children who developed sepsis and meningitis. Some studies 
suggest that severe NDI might be lower in children develop-
ing sepsis compared to meningitis23,24. However, since sepsis 
is more common among neonates with serious bacterial infec-
tion in LMIC settings5, even mild NDI could make an impor-
tant contribution to the overall morbidity of iGBS. In addition 
to the risk of long-term morbidity, iGBS may also lead to excess 
mortality after the acute episode. Although our study is not 
powered to compare mortality risk in iGBS survivors versus 
those without history of iGBS, we will be able to describe 
mortality and causes of deaths in four of five sites.
Another strength of our study is the collection of primary data 
on healthcare use, income, and HRQoL across multiple coun-
tries, which will enable us to identify where iGBS disease may 
lead to worse outcomes. Adverse economic outcomes due to 
iGBS are thought to be likely, for example costs linked to seque-
lae that necessitates frequent healthcare utilization, costly 
household adaptations, and additional time spent on caregiving 
to support a child with disabilities21,25. However, to our knowledge, 
only one study in the UK has directly measured the economic 
costs of iGBS. In that study, where children were followed-up 
to the age of two, the average health and social care costs were 
substantially higher amongst those with history of iGBS13.
A major challenge of this study is the use of different develop-
mental assessment tools in each country, and the complexity 
of combining multi-domain and neurodevelopmental outcomes 
for different age bands and multiple tests. We will try to 
ensure measurement equivalence and comparability of the 
NDI outcomes between different ages, assessment tools and 
sites through domain mapping of assessment tools, before 
individual-level data from each site is further combined for 
analysis.
A further challenge is the impact that the global coronavirus 
(COVID-19) pandemic will have on recruitment and research 
activities, which are not clear. We will continue to assess the 
situation and are working closely with research teams from each 
and collaborative institutes to safely undertake field activities 
in line with each country’s guidelines.
Findings from this study will be used to update previous mor-
bidity estimates of the burden of infant iGBS disease12, adding 
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relevant data on long-term outcomes. This will include informa-
tion to estimate lifetime disability, including risk of NDI, and 
societal impacts following GBS-related sepsis and meningitis. 
These additional morbidity estimates, combined with the pre-
viously published data on mortality and morbidity of pregnant 
and postnatal women and stillbirths, along with other literature, 
will serve as data inputs for both mother and infant GBS dis-
ease to update estimates of the overall public health burden of 
iGBS. Disease burden estimates will be translated into DALYs 
incurred based on the latest available epidemiologic data, while 
responses to the quality of life instruments combined with 
mortality data will be used to estimate QALYs lost. These estimates 
will be an important input feeding into future cost-effectiveness 
analyses.
Our findings will contribute to a WHO value proposition on 
GBS maternal immunization to inform strategic planning of 
GBS vaccine research, development, and future implementa-
tion. Decision making by multiple stakeholders in the GBS 
vaccine development process, including research funders, manu-
facturers, donors and national governments, will be shaped by 
these findings. Data generated from this study will be linked 
with research outputs providing more regional and country 
specific details, allowing countries to utilize the findings in their 
own context. This will help reduce the translational, marketing, 
and implementation gaps for the development and introduction 
of a new GBS vaccine in LMICs which experience some of 
the highest disease burden.
Most of the mortality and morbidity of iGBS occurs in low-
resource settings where there continues to be a paucity of data. 
As well as the limited epidemiological and clinical data, there 
are major gaps in data on the economic burden of both short-
term and the long-term effects of iGBS. Our study will address 
limitations in the data currently available, providing new data on 
epidemiological and economic outcomes are needed to get a 
more complete picture on the consequences of iGBS for indi-
viduals and their families. Coordinated data collection across dif-
ferent settings together with harmonized analysis approaches, 
will maximize the value of the collected data. The results of our 
study will support development and investment in cost-effective 
strategies to minimize the iGBS burden and improve the chances 
for children to survive, thrive and reach their developmental 
and economic potential.
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The description of a multi-country protocol to quantify the acute costs and the long-term health 
and economic outcomes of survivors of invasive GBS disease is clear, concise, and timely. The 
rationale, that the results of this study provided essential input to a full value of vaccine 
assessment (aka full public health value preposition, FPHVP), is also clear and convincing. 
 
Two major questions come to this reviewer's mind when reading this manuscript:
Sample size and power calculation: this description appears to describe an approach for 
determining whether there is a statistically significant difference between the iGBS survivors 
group and the the matched non-iGBS control children for certain specific outcomes. That 
there is a statistically significant difference between the two groups is certainly of some 
interest, but would seem not to be the critical input data for a FPHVP assessment. Rather it 
would seem that the critical information would be: 1) an absolute point estimate and 
confidence intervals thereof of burden of disease outcomes that are the major value drivers 
in the FPHVP; and 2) the excess burden of disease (see point 2 below) in iGBS survivors that 
are the major value drivers in the FPHVP. Perhaps the data analyses and statistical 
methodology that support these two estimates, with confidence intervals, is in the protocol, 
but if not, the authors should be encouraged to add and describe those items. 
 
1. 
Inclusion and exclusion criteria: Again, perhaps the information is provided in the protocol; 
however, it is unclear what the inclusion and exclusion criteria of selecting iGBS survivors, 
and equally important the case controls, with respect to other potential causes of the 
endpoints being measured. For example, NDI is multifactorial, including both genetic and 
infectious disease etiologies. Congenital CMV is a major, if not most frequent, cause of 
neonatal infectious disease-associated NDI in high-income countries. While there are data 
gaps in LMICs, accumulating evidence suggests CMV will also be a major contributor to 
congenital/neonatal NDI. It would seem prudent that some attempt at capturing other 
frequent causes of the endpoints studied, and either inclusion/exclusion criteria defined, or 
at least stratified analyses of the data by those other causes (if known).
2. 
All in all, this multi-country study has a reasonable likelihood of collecting a critical set of input 
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data for determining if and how compelling the FPHVP is for developing vaccines or other 
interventions to protect against in utero, early and late onset iGBS.
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